Lek to construct 6.7M euro biopharma site
Slovenian drugmaker Lek, part of Novartis' Sandoz generics division, says that it is to develop and construct a new biopharmaceuticals development center on the outskirts of the country's capital, Ljubljana. The announcement, which was made during chief executive Janja Bratos' speech marking the company's 60th anniversary, also detailed the firm's plan to consolidate its leading position in the field of biopharmaceuticals.
Company focussed on biopharmaceuticals
According to Lek, the new facility, construction of which began this fall, will be a 2,800m2 site that will accommodate 100 experts in a diverse range of scientific disciplines, including biology, chemistry and pharmacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze